Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
CSP.L Share News (CSP)
CSP Share
Price
CSP Share
News
CSP Share
Chat
CSP Share
Trades
CSP
Live RNS
CSP Share
Charts
CSP Broker
Ratings
CSP Directors
Deals
CSP Financial
Diary
CSP
Fundamentals
CSP Short
Positions
CSP
Media
CSP Company
Research
CSP Company
Timeline
- There is currently no data for CSP
Wednesday broker round-up
Barclays: Berenberg reiterates buy with a target price of 220p.
Aston Martin: Citigroup reiterates buy with a target price of 2,800p.
Segro: JP Morgan reiterates neutral with a target price of 1,195p.
Sainsbury: Barclays reiterates overweight with a target price of 305p.
GlaxoSmithKline: Liberum reiterates buy with a target price of 1,700p.
On The Beach: Liberum reiterates hold with a target price of 380p.
888 Holdings: Peel Hunt reiterates buy with a target price of 500p.
Countryside Properties: Peel Hunt reiterates buy with a target price of 560p.
Redrow: Numis reiterates buy with a target price of 715p.
Accesso: Numis upgrades to buy with a target price of 800p.
International Airlines Group: Credit Suisse reiterates outperform with a target price of 256p.
Centrica: Credit Suisse reiterates outperform with a target price of 70p.
Latest CSP News
- Countryside Properties on track for full year; COO steps down
17 Apr 2019 - UK Earnings, Trading Statements Calendar - Next 7 Days
10 Apr 2019 - FTSE 250 movers: Funding Circle flounders, Amigo arises
5 Apr 2019 - Countryside is star buy for Jefferies in upbeat housebuilders report
2 Apr 2019 - Countryside Properties Appoints Ei CEO Townsend As Non-Executive
15 Feb 2019 - Countryside Properties Q1 completions lifted by affordable housing
24 Jan 2019 - UK Shareholder Meetings Calendar - Next 7 Days
17 Jan 2019 - FTSE 250 movers: Premier and Page slide, JD scores gains
14 Jan 2019
Related News
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
* GSK partner Hansoh reports first late-stage data for experimental lung cancer drug
GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...
GSK hails 'milestone' drug trial results in China
(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...
CSP.L News
Countryside Properties on track for full year; COO steps down
(Sharecast News) - Housebuilder Countryside Properties said on Wednesday that it was on track to deliver full-year results in line with expectations a...
UK Earnings, Trading Statements Calendar - Next 7 Days
Thursday 11 April WH SmithHalf Year Results easyHotelTrading ResourcesQ1 12
FTSE 250 movers: Funding Circle flounders, Amigo arises
(Sharecast News) - London's FTSE 250 index was 0.07% lower at 19,492.70 in afternoon trade on Friday, with Funding Circle leading the index lower.
Countryside is star buy for Jefferies in upbeat housebuilders report
(Sharecast News) - Countryside is the star share among UK housebuilders, Jefferies said as it started coverage of the industry with an upbeat report.
Countryside Properties Appoints Ei CEO Townsend As Non-Executive
LONDON (Alliance News) - Countryside Properties PLC on Friday said it has appointed Simon Townsend as non-executive director of the company with effec...
Countryside Properties Q1 completions lifted by affordable housing
(Sharecast News) - Housebuilder and urban regenerator Countryside Properties posted a jump in first-quarter completions on Thursday as affordable hous...
UK Shareholder Meetings Calendar - Next 7 Days
Friday 18 January IxicoMonday 21 JanuaryPlus500 (EGM re revised director 22 &
FTSE 250 movers: Premier and Page slide, JD scores gains
(Sharecast News) - London's FTSE 250 was down 0.7% at 18,410.02 late on Monday, with Premier Oil and PageGroup leading the retreat.
Follow the stocks
